Background and Purpose-Stroke outcomes in patients with atrial fibrillation (AF) tend to be worse than those in patients without AF. The objective of this study was to evaluate whether the cost benefits of anticoagulation for stroke prevention in AF may currently be underestimated by existing economic models that do not distinguish between different stroke outcomes. Methods-A literature review was conducted in 3 areas: (1) studies comparing stroke outcomes in AF and non-AF patients;
R
ecent years have seen an increasing emphasis on the use of health economic data, in conjunction with evidence of clinical effectiveness, for the development of clinical guidelines. 1, 2 This is particularly important for stroke, a disease characterized by a high prevalence, as well as a high burden of illness and economic cost, but in which preventive strategies such as blood pressure control, smoking cessation, diet and exercise have been shown to be effective. Of the preventive measures for stroke in patients with atrial fibrillation (AF), anticoagulation has been associated with the greatest benefits, resulting in a 67% to 80% reduction in the risk of stroke. 3 Atrial fibrillation affects Ϸ5% of all elderly people and increases the risk of stroke 5-fold compared with patients in normal sinus rhythm. 4, 5 Because both the incidence of AF and the stroke risk attributable to AF increase with age (the latter being 1.5% at age 50 to 59 years; 9.9% at 70 to 79 years; and 23.5% at 80 to 89 years), AF and stroke will pose major societal costs over the coming decades. 4,6 -9 Cost-effectiveness models of anticoagulation for the prevention of stroke in patients with AF are based on the incremental change in costs and outcomes (eg, qualityadjusted life years) associated with anticoagulant therapy, treatment-related bleeding events, and ischemic strokes. The objective of this review was to evaluate whether the cost benefits of anticoagulation for stroke prevention in AF may currently be underestimated by existing economic models that do not account for the different outcomes of cardioembolic stroke in people with AF compared with strokes in patients without AF. A literature review was conducted in 3 areas: (1) studies comparing stroke outcomes in patients with and without AF; (2) studies providing long-term cost-ofstroke estimates; and (3) studies modeling the costeffectiveness of anticoagulation.
Materials and Methods
We conducted a literature review of studies comparing stroke outcomes in patients with and without AF, studies estimating the cost of stroke, and studies modeling the cost-effectiveness of anticoagulation. Searches were conducted on MEDLINE in December 2003, including results from 1966 up to that date, with the following search criteria: "stroke outcome/severity/cost" AND "atrial fibrillation;" "cost/cost-effectiveness/economic evaluation" AND "anticoagulation" AND "atrial fibrillation." The initial search identified 114 articles. Studies reporting primary data analysis, economic models, or cost-of-stroke data with at least 1 year of follow-up were selected for inclusion. The final analysis included 14 studies comparing stroke outcomes in AF and non-AF patients, 15 cost-of-stroke studies, and 9 cost-effectiveness modeling studies.
Results

Stroke Outcomes in AF
Earlier studies of stroke outcomes focused on mortality and stroke recurrence rates, whereas later studies have considered stroke severity in addition to functional and neurological impairment among stroke survivors. Collectively, studies analyzing Ϸ10 000 strokes clearly demonstrate that stroke in patients with AF has worse outcomes than strokes in patients in sinus rhythm (non-AF stroke) ( Table 1) . 10 -23 Overall, ischemic stroke associated with AF is approximately twice as likely to be fatal as non-AF stroke. Adjusting for age and comorbidities, short-term mortality rates from stroke (in-hospital or 1 month after stroke) were significantly increased in the presence of AF 10,12-17,19 -21 (19% to 35%) compared with no AF (5% to 14%; Table 1 ). 10, [12] [13] [14] 16, 19 Atrial fibrillation also independently predicted higher 3-month stroke mortality after controlling for age, gender, and other baseline variables, 10 higher mortality 1 year after stroke in multivariate analyses, 18, 19, 22 and higher relative risk of death at 6 months. 13 At 6 months 11 and 1 year 19, 22 after an initial stroke, recurrence rates are Ն2-times higher in patients with AF compared with those without AF (Table 1) . Various studies have demonstrated more severe (larger) brain lesions, 12,17,20 a greater incidence of abnormal computed tomograms, 13 and more patients with cortical involvement (68% versus 43%) 20 or an anterior circulation infarct (34% versus 25%) 10 among stroke patients with AF. Stroke was more likely to be severe (evaluated on the basis of neurological impairment during the initial hospitalization) or fatal in subjects with AF, 19 and it was associated with worse scores on the Canadian Neurological Scale, 17 Scandinavian Neurological Stroke Scale, 20 and National Institutes of Health Stroke Scale. 21 The frequency of bedridden state after stroke was also higher among AF patients (41% versus 24%), was correlated with other clinical severity data, and independent of age and other stroke risk factors. 23 The Copenhagen study 20 found significantly longer hospital stays from the time of acute admission to the end of rehabilitation among AF stroke patients compared with non-AF stroke patients in a stroke unit (50 versus 40 days). However, in the European BIOMED study, 10 mean length of stay in general acute care hospitals was not significantly different between groups, but inter-unit variability in routine length of stay across 22 stroke units in 7 countries may have contributed to masking any differences between AF stroke and non-AF stroke patients.
Stroke in patients with AF is associated with more impairment measured by the modified Rankin Scale at 30 days, 17 3 months, 10 and 1 year, 22 as well as with greater dependency measured on the Barthel Index in the acute phase, 19 at 3 months, 10, 19 and at 6 months (Table 1) . 19 For example, 33% of non-AF patients had acute severe dependency, and this decreased to 16% at 3 and 6 months, whereas among AF patients 73% had severe dependency in the acute phase, 58% at 3 months, and 36% at 6 months. 19 Two studies 10, 20 have shown that a significantly lower proportion of AF stroke patients are discharged to their own home (Table 1) , although these analyses did not adjust for age. In addition, 30% more patients with than without AF were institutionalized (9% versus 6%, respectively). 10 
Cost of Stroke
Long-term cost estimates show that the cost of stroke is substantial in all countries. 24 -40 Lifetime estimates of the cost of a stroke per patient range between US $25 558 (all stroke types) and US $142 251 (major ischemic stroke) after adjustment to dollars and 2004 prices (base costs, Swedish krona 180 000 in 1991 26 and £75 985 in 1996, 34 respectively). Three publications reported costs for strokes of different severities (Table 2) . 26, 34, 35 The cost increments were between 1.5-and 3-fold. The lowest cost was for all mild strokes over 5 years (US $24 991) 35 and the highest was for a major ischemic stroke over a lifetime (US $142 251, as noted). 34 Importantly, no publications were found reporting costs of stroke specifically for a population with AF. It has been shown that hospitalized AF patients incur higher costs than matched patients without AF, 41 although interventions for the arrhythmia, such as cardioversion, would have contributed to the cost differential in this analysis.
Economics of Anticoagulation
The cost-effectiveness of anticoagulation among AF patients classified as high-risk of stroke is clearly established, whereas cost-effectiveness estimates among patients at lower risk may be more sensitive to the input assumptions of economic models. The findings of the economic models shown in Table  3 represent the current body of cost-effectiveness evidence. 33, [42] [43] [44] [45] [46] [47] [48] The results of all of these studies show that in medium-to high-risk patients with AF or older patients with AF, whether male or female, anticoagulation is dominant (increases quality-adjusted life-years and is cost-saving) or has a low marginal cost-effectiveness ratio (a low additional cost per quality-adjusted life-year gained) in comparison with no anticoagulant therapy 33,42,46 -48 and in comparison with aspirin, 44, 45 whereas low-risk AF populations are associated with a higher marginal cost-effectiveness ratio. 45 The cost of AF strokes in these models will be characterized by the severity distribution used and the average "unit" costs attached to each stroke severity category. Table 4 shows the distributions of stroke event severity that were used in 5 published economic models. Four use the severity distribution observed in randomized controlled trials of anticoagulation in AF patients rather than from unselected patients in routine clinical practice. 33, 44, 45, 47 One of these is based on a single, small study (nϭ420) in which only 15 strokes occurred. Thomson et al 46 state that no valid published studies reported the risk of different outcomes after stroke associated with AF. Only Thomson et al use epidemiological data for severity-based on a personal communication with the Oxfordshire Community Stroke Project. Perhaps as expected, the proportion of fatal strokes in this study using epidemio- logical data are higher than in those using data from clinical trials ( Table 4) .
None of the 5 cost-effectiveness models for anticoagulation in patients with AF uses AF-specific stroke cost data. Instead, more generic stroke cost and price estimates are used. As with the long-term estimates illustrated in Table 2 , the costs applied to stroke events vary with the sources of data, assumptions, and the extrapolated time periods used. The acute (one-time) cost of severe stroke has been considered to be 2.8-fold 46 or 3.5-fold 44, 45 that of mild stroke. These costs are then weighted based on the assumed severity distribution of strokes. Estimates of the cost of long-term care and the proportion of patients requiring nursing home care used in cost-effectiveness models also vary. 44, 45, 47 Again, these are not based on resource use evaluated from an AF population.
Discussion
Economic models to assess the cost-effectiveness of anticoagulation in AF for the primary prevention of ischemic stroke are based on 3 input parameter estimates, namely the change (compared with most relevant alternative therapy) in cost and quality of life associated with: (1) the anticoagulant therapy itself; (2) adverse (bleeding) events; and (3) ischemic stroke events. These parameters are a function of factors such as the differential risk of events, health care, patient resource use associated with management processes, and treatment process utilities (ie, quality-of-life estimates).
There is considerable evidence that stroke in patients with AF has worse outcomes than non-AF-related strokes, including higher mortality, severity, and recurrence rates and greater functional impairment and dependency. These factors suggest that AF strokes have a higher cost compared with strokes not related to AF. Therefore, the case for costeffectiveness of anticoagulation therapy, which has been demonstrated in existing economic models, is likely to be even stronger when using higher cost-of-stroke estimates based on events in patients with AF.
The monetary valuation placed on stroke events is a key component of the economic assessment of events that could be avoided by anticoagulation. Large variations arise because of the different ways that stroke services are organized and the different service needs of different subpopulations. In particular, the length of acute stay, type of acute care ward, the existence of hospital-based rehabilitation, and staff skills mix vary considerably and are key drivers of acute care costs. 49 Variation in postacute care services is even greater. Impairment and dependency increase the need for health and social services and family support. Discharge from hospital to a residential or nursing home represents the largest share of total costs. However, rehabilitation services and institutional care are not formally provided in many health care systems; therefore, a great deal of the unpaid informal care is not included in the cost estimates. 49 The different service needs of different subpopulations are relevant to the potential underestimate of the average costs of stroke typical in AF patients compared with non-AF-related or total stroke events. Data sources for resource use and survival are important to the reliability of cost estimates. For resource use, studies rely on prospective data obtained from stroke registries, clinical or economic trials, and published or other expert opinion. For survival, longer-term epidemiological data are available, but there is a paucity of longer-term observational studies of stroke patients reporting cost data. Most economic studies of stroke follow-up patients for 1 or 2 years and use modeling techniques to extrapolate to lifetime costs (10 to 15 years for this population) based on mortality, progression through disability levels over time, and correlations between disability levels and cost. Generally, cost models based on studies with a longer time period of actual patient-specific resource use data will be more reliable. OCSP indicates Oxfordshire Community Stroke Project; RCT, randomized controlled trial. *Local currency costs from the base year were adjusted to estimated 2004 costs, applying the US inflation rate (Consumer Price Index) for the appropriate period to all countries. 39 Costs were then converted to US dollars using purchasing power parities (PPPs) for the most recent year available (2003). 40 2003 PPPs: US ($) ϭ 1.0; Australia (Aus $) ϭ 1.37; UK (£) ϭ 0.638.
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One implication of greater mortality among patients with AF-related stroke is a reduced population of survivors incurring long-term costs. However, in economic analyses death remains a negative outcome, so the value of more premature deaths avoided (years of life gained) by stroke prevention among AF patients must be realistically incorporated into cost-effectiveness estimates. 50 The increased recurrence rate associated with AF stroke also has to be accurately represented in economic analyses in terms of additional costs and years of life lost, because recurrent strokes tend to be more severe and more often fatal than first strokes. 37 It has been demonstrated that initial stroke severity (not age or comorbidity) is a significant predictor of length of initial hospital stay. 20, 51 In addition, stroke characteristics will influence duration of survival and disability (and consequently the costs of long-term care), whether defined by disease subtype, 52 Barthel score, 53 or Rankin score. 37 Admission to a nursing home, which has a large impact on total cost, is more likely in patients with severe stroke. Evidence exists for a positive correlation between severity of stroke and longer-term stroke costs, 49, 53 which will have implications for AF-related strokes. Limited evidence is available to compare average survival time after stroke, but 5-year mortality after a stroke was shown to be higher (78%) among patients with AF than among those in sinus rhythm (52%). 14 Although models assessing the cost-effectiveness of anticoagulation in AF patients use outcome data from AF populations in clinical trials, it is unclear whether the AFrelated strokes that occur in these trials are typical (in terms of frequency and severity) of those that occur in real-life clinical practice (eg, anticoagulant intensity may be less well-controlled in real life than in a trial setting; age and comorbidities among the populations may be different). Stroke occurring in patients at subtherapeutic International Normalized Ratio values are more severe than those in patients with a therapeutic intensity of anticoagulation. 54 Epidemiological studies may be more informative on these issues than clinical trials. Some studies have used the Framingham 55 or other population data for calculation of the absolute risk of stroke, 42, 46 but Thomson et al 46 acknowledge that the risk was derived from data from the entire Framingham cohort, not just those with AF, and that regression equations tend to underestimate risk in those at the higher end of the range. Hence, the absolute risk of stroke in patients with AF may be underestimated in their model.
Among the practical limitations of warfarin is its variable anticoagulant effect. The fear of causing bleeding is one reason why anticoagulation is underused, particularly in the most elderly, despite the fact that they generally have the highest risk of stroke. Some investigators have found a higher incidence of bleeding in elderly patients receiving warfarin, 56 whereas others suggest that more studies are needed that better-estimate the risk of intracranial bleeding with and without anticoagulation. 47 Most clinical trials of anticoagulation do not include this age group. Therefore, an important part of the research agenda should be to understand the benefit/risk relationship, ideally in a study that includes an economic analysis. If the effectiveness and safety of anticoagulation (whether in usual [ambulatory] care or in an anticoagulation clinic setting) can be demonstrated in this age group, then the economic gain could be further emphasized.
The extent of potential underestimation of the unit cost of stroke needs to be explored further, and our key recommendation for new research is to conduct a study to collect long-term costs of stroke in patients with AF (compared with non-AF patients). This would permit new economic analyses on existing raw data from published trials using more specific (presumably higher) cost-of-stroke data. If also applied to new clinical efficacy studies (such as among the elderly or people at lower risk of stroke), it would inform about cost-effectiveness in different groups of patients. This research is urgent because underestimation of the value of anticoagulation will affect clinical practice.
